Opioid Use Disorders. Opioid abuse
Conditions
Interventions
Intervention 1: Control group: after emergence of withdrawal symptoms, an average of 2 mg of buprenorphine is started in two divided doses and if needed, 2 mg of buprenorphine up to a maximum of 8 mg
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 18 Years
Inclusion criteria
Inclusion criteria: Diagnosis of opioid use disorder based on DSM-5 by a child and adolescent psychiatrist age 5-18 years old
Exclusion criteria
Exclusion criteria: Allergy to buprenorphine or clonidine or gabapentin. Chronic or inflammatory diseases (heart, lung, liver, kidney or neurological diseases such as epilepsy). Serious psychiatric illnesses such as schizophrenia and other psychotic disorders, acute phase of bipolar disorder and moderate to severe mental disability. Dissatisfaction of the patient's parent or Legal guardian to continue the plan.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Withdrawal symptoms according to psychiatrist examination and patient report. Timepoint: days 1 to 14. Method of measurement: Clinical opioid withdrawal scale and subjective opioid withdrawal scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug side effects. Timepoint: day 1 to 14. Method of measurement: Checklist of drug side effects. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mahin Eslami Sharbabaki
Kerman University of Medical Sciences
Outcome results
None listed